

## Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
<b>Au</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Choi</b>	Speaker	<ul style="list-style-type: none"> <li>Intercept</li> </ul>	<ul style="list-style-type: none"> <li>Speakers Bureau</li> </ul>
<b>Deising</b>	Speaker	<ul style="list-style-type: none"> <li>Salix, Mallinckrodt</li> </ul>	<ul style="list-style-type: none"> <li>Speaker</li> </ul>
<b>Frias</b>	Speaker	<ul style="list-style-type: none"> <li>Akero Therapeutics, Boehringer Ingelheim, Carmot Therapeutics, 89Bio, Metacrine, Pfizer</li> <li>Echosens</li> <li>Eli Lilly, Merck, Novo Nordisk, Sanofi</li> <li>Intercept, IONIS, Janssen, Madrigal, NorthSea Therapeutics, Oramed</li> </ul>	<ul style="list-style-type: none"> <li>Research funding, consultant</li> <li>Consultant, speaker</li> <li>Research funding, consultant, speaker</li> <li>Research funding</li> </ul>
<b>Gish</b>	Speaker	<ul style="list-style-type: none"> <li>Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, Venatorx</li> <li>Gilead Sciences, Inc</li> <li>AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant,, Intercept, Janssen, Merck, Pfizer, Prodigy</li> <li>Topography Health</li> <li>Prodigy</li> <li>Fibronostics, Fujifilm/Wako, Perspectum, Quest, Sonic Incytes</li> <li>Altimune, Arrowhead, CymaBay Therapeutics, Durect</li> <li>AbbVie, BMS, Eisai, Genentech, Gilead Sciences Inc., Intercept</li> <li>RiboSciences, CoCrystal</li> <li>Eiger, Genlantis, HepQuant, AngioCrine, HepaTx</li> </ul>	<ul style="list-style-type: none"> <li>Consultant, Advisor</li> <li>Research grant/support</li> <li>Advisory Board</li> <li>Clinical trial alliance</li> <li>Chair Clinical Advisory Board</li> <li>Advisory Consultant</li> <li>Data Safety Monitoring Board</li> <li>Speaker</li> <li>Minor stock shareholder</li> <li>Stock Options</li> <li>Consultant</li> </ul>

		<ul style="list-style-type: none"> <li>Abbvie, Abbott, Access Biologicals, Active Genome Expressed Diagnostics,ADMA Biologicc, AEC partners, Alogos Therapeutics, Arena Pharmaceuticals Inc, Ark Biopharmaceutical Arrowhead, arterys, Inc, Alexion, Altimune, Antios Therapeutics, AproxTX, Ark Biopharmaceutical Co Ltd, Audentes Therapeutics, Bayer, Cirina, Consumer Health Products. CymaBay, Diasorin, Dova, DRG Abacus, Durect Corpotation, Dynavax, Exhosens, Eiger, Eisai, Enyo, Exelixis, Fibronostics Inc, Forty-Seven Inc, Fujifilm Wako Diagnostics, Gilead Sciences, HepQuant, HepTX, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen, KannaLife, Kezar Life Sciences, LabCorp, Laboratory for Advanced Medicine, Labyrinth Holds, Life Line Screening, Eli Lilly, MedImmune, Merck, New Enterprise associates, Ogilvy CommunHealth, Organova, Patient Connect, Persectum, Pfizer, Pharmaceutical Research Associates, Prodigy Biotech, Prometheus Laboratorie, Refuah Solutions, Regulus Therapeutics, Sagimet Inc, Salix, Saol Bermuda Ltd, Shenzhen HEC Industrial Development, Shionogi Inc, Spring Bank, Tonghua Anrate Biopharmaceutical, Topography Health, Trimaran, Venatorx, Venatorx, Viravaxx</li> </ul>	
<b>Gunn</b>	Speaker	<ul style="list-style-type: none"> <li>Gilead</li> <li>89bio, Salix, Akero, Altimune, Boehringer-Ingelheim, Braintree, Carcept, Eli Lilly, Galectin, Gilead, High Tide, Inventira, Kowa, Madrigal, Novo Nordisk</li> </ul>	<ul style="list-style-type: none"> <li>Speaker</li> <li>Researcher</li> </ul>
<b>Gutierrez</b>	Course Director, Moderator	<ul style="list-style-type: none"> <li>Abbvie, Gilead, Exelixis, Intercept</li> <li>Altimunec, Livivos</li> <li>Alexion</li> </ul>	<ul style="list-style-type: none"> <li>Consultant, Speaker</li> <li>Consultant</li> <li>Speaker</li> </ul>
<b>Kowdley</b>	Speaker	<ul style="list-style-type: none"> <li>CymaBay, Genfit, Gilead, GSK, HighTide, Inipharm,Intercept, Madrigal, Mirum, NGM, Pfizer, 89bio</li> <li>Corcept, CymaBay, Genfit, Gilead, GSK, Hanmi,Intercept, Madrigal,</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Research</li> <li>Speaker Bureau</li> <li>Stock Options</li> </ul>

		Mirum, Novo Nordisk, NGM, Pfizer, Pliant, Terns, Viking, 89bio <ul style="list-style-type: none"> <li>AbbVie, Gilead, Intercept</li> <li>Inipharm</li> </ul>	
<b>Lee</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Martin</b>	Speaker	<ul style="list-style-type: none"> <li>AbbVie</li> <li>Theratechnologies, Mallinckrodt, Genefit, Durect, Grifols</li> <li>Seral Trials, Vikings, Enanta</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Research Funding</li> </ul>
<b>Martinez</b>	Speaker	<ul style="list-style-type: none"> <li>AbbVie, Gilead</li> <li>Roche, Sirtex</li> </ul>	<ul style="list-style-type: none"> <li>Speaker, Contractor</li> <li>Contractor</li> </ul>
<b>Noureddin</b>	Speaker	<ul style="list-style-type: none"> <li>89bio, Altimune, Blade Therapeutics, Inc, EchoSens, Fractyl, Gilead Sciences, Inc, cohBar, Cytodyn, Intercept Pharmaceuticals, Pfizer, Novo Nordisk, Madrigal, Terns, Roche Diagnostic, Siemens</li> <li>Allergan, Bristol Myers Squibb, Gilead Sciences, Inc, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking Therapeutics, Inc. Zydus</li> </ul>	<ul style="list-style-type: none"> <li>Advisory Board</li> <li>Research Grants</li> </ul>
<b>Pockros</b>	Course Director, Moderator	<ul style="list-style-type: none"> <li>Intercept Pharmaceuticals</li> <li>Gilead Sciences, Inc</li> <li>F5 Therapeutics</li> <li>Altimune, Boston Pharmaceuticals</li> <li>Durect Corporation, GSK</li> </ul>	<ul style="list-style-type: none"> <li>Speaker, research funding paid to Scripps Health, consultant</li> <li>Consultant, research funding paid to Scripps Health</li> <li>Stock options</li> <li>Data Safety Monitoring Board</li> <li>Advisory Board</li> </ul>
<b>CME Committee</b>	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Scripps Conference Services &amp; CME</b>	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>

### Glossary of Terms

#### Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit [www.accme.org/standards](http://www.accme.org/standards).

#### Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.